Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

By R. Levine, C. Lam, Cong Qian, Kai-fun Yu, S. Maynard, B. Sachs, B. Sibai, F. Epstein, Roberto Romero, R. Thadhani and 1 more. New England Journal of Medicine, 2006

1,791 citations recorded by the source corpus.

Subfields: Immunology, Obstetrics and Gynecology

View Paper: https://www.semanticscholar.org/paper/ac587fbb18900e3d0ad244e0b4bec06cfe250208

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Roberto Romero
2. T. Chaiworapongsa

In Obstetrics and Gynecology

1. Roberto Romero
2. T. Chaiworapongsa

Citations in the corpus

• Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia (2012, neutral): “001 ALT in Triage (U/L) 15 (12-21) 16 (12-23) 0.”
• A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate (2008, background): “Our results are consistent with recent reports that PE is associated with an anti-angiogenic state, as demonstrated by high plasma concentrations of sVEGFR-1 [16,19–21] and s-Eng [26,27], and low plasma or serum concentrations of PlGF [16,19,28].”